Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515247-28-00

Acronym

104317

Enrollment

Registered

2024-07-30

Start date

2019-03-29

Completion date

2025-10-03

Last updated

2025-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypereosinophilic Syndrome

Brief summary

"SAEs Non-serious AEs related to mepolizumab as assessed by the Investigator Mean 28-day SC dose (mg) for the last 3 administrations"

Interventions

None listed

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
"SAEs Non-serious AEs related to mepolizumab as assessed by the Investigator Mean 28-day SC dose (mg) for the last 3 administrations"	—

Countries

Poland

Outcome results